Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]

Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma

Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City...

Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma ( Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City, USA )

Comment: Targeted therapy ivosidenib in cholangiocarcinoma

Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK

Comment: Targeted therapy ivosidenib in cholangiocarcinoma ( Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK )

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019

Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019 ( Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith )

BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF...

Prof Josep Tabernero - Vall d´Hebron Institute of Oncology (VHIO), Barcelona...

BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer ( Prof Josep Tabernero - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Comment: Veliparib with carboplatin and paclitaxel in advanced gBRCA-positive...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

Comment: Veliparib with carboplatin and paclitaxel in advanced gBRCA-positive breast cancers ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in...

Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California

CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-positive HER2-negative breast cancer ( Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California )

CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR...

Prof George Sledge - Stanford Health Care, Stanford, USA

CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-negative advanced breast cancer ( Prof George Sledge - Stanford Health Care, Stanford, USA )

Comment: CDK4/6 inhibitors in advanced breast cancer

Prof Nadia Harbeck - University of Munich, Munich, Germany

Comment: CDK4/6 inhibitors in advanced breast cancer ( Prof Nadia Harbeck - University of Munich, Munich, Germany )

Immunotherapy added to chemotherapy improves pathological complete response in...

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

Immunotherapy added to chemotherapy improves pathological complete response in early triple negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )

Ovarian highlights from ESMO 2019

Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA

Ovarian highlights from ESMO 2019 ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )

VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian...

Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA

VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )

Comment: Osimertinib for EGFR-mutation positive NSCLC

Dr Pilar Garrido - University Hospital Ramón y Cajal, Madrid, Spain

Comment: Osimertinib for EGFR-mutation positive NSCLC ( Dr Pilar Garrido - University Hospital Ramón y Cajal, Madrid, Spain )

More from ecancer